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Abstract
Background: Clinically significant drug-drug interactions (CSDIs) involving antiretrovirals are frequent and under-recognized
in developed countries, but data are lacking for developing countries.
Methodology and Principal Findings: To investigate the prevalence of CSDIs between antiretrovirals and coadministered
drugs, we surveyed prescriptions dispensed in a large HIV clinic in Kenya. Of 1040 consecutive patients screened, 996 were
eligible for inclusion. CSDIs were defined as ‘major’ (capable of causing severe or permanent damage, contraindicated, avoid
or not recommended by the manufacturer, or requiring dose modification) or ‘moderate’ (manufacturers advise caution, or
close monitoring, or capable of causing clinical deterioration). A total of 334 patients (33.5%) were at risk for a CSDI,
potentially lowering antiretroviral drug concentrations in 120 (12%) patients. Major interactions most frequently involved
rifampicin (12.4%, mostly with efavirenz) and azoles (2.7%) whereas moderate interactions were frequently azoles (13%),
steroids (11%), and antimalarials (3%). Multivariable analyses suggested that patients at risk for CSDIs had lower CD4 counts
(P = 0.006) and baseline weight (P = 0.023) and WHO Stage 3 or 4 disease (P#0.007). Risk for CSDIs was not associated with
particular regimens, although only 116 (11.6%) patients were receiving WHO second line regimens.
Conclusions: One in three patients receiving antiretrovirals in our programme were at risk of CSDIs. Strategies need to be
urgently developed to avoid important drug interactions, to identify early markers of toxicity and to manage unavoidable
interactions safely in order to reduce risk of harm, and to maximize the effectiveness of mass antiretroviral deployment in
Africa.
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Introduction
The introduction of combination antiretroviral therapy has
remarkably improved survival of HIV infected persons [1]. Of the
five main classes of antiretrovirals, only nucleoside reverse
transcriptase inhibitor (NRTIs), non-nucleoside reverse transcrip-
tase inhibitor (NNRTIs) and protease inhibitors (PIs) are widely
available for treatment of HIV in sub-Saharan Africa.
NNRTIs and PIs undergo biotransformation by cytochrome P-
450 (CYP) enzymes, thus making them prone to clinically
significant drug interactions (CSDI) when combined with other
drugs metabolised via the same pathway. In addition they interact
with other medications, acting as either inducers or inhibitors of
CYP enzymes. Further, PIs are substrates and/or inhibitors of
drug transporters such as P-glycoprotein which may result in
pharmacokinetic drug interactions [2–4]. Although most NRTIs
are renally excreted, there remains a potential for drug
interactions [2,3]. Managing drug-drug interactions is one of the
major challenges in the optimisation of HIV therapy [5,6]. CSDIs
have previously been reported to be prevalent in developed
countries (affecting 20–41% patients) [7–11], but data from
developing countries are lacking. HIV infected individuals in
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Africa often present late, with acute opportunistic infections and
other AIDS-associated conditions which require multiple other
medications thus increasing the potential for CSDIs.
USAID-AMPATH is a partnership between Indiana University
School of Medicine and Moi University School of Medicine
(Kenya) and is one of Africa’s largest antiretroviral programs. It is
based at the Moi Teaching and Referral Hospital. During the
period of study AMPATH cared for more than 55,000 HIV
infected adults and children, with nearly one-half of all patients on
antiretroviral drugs, and enrolment into the program was
increasing by 2,000 patients per month [12]. In this prospective
observational survey, we investigated the frequency of CSDIs in
follow up prescriptions for 1000 consecutive patients enrolled into
the AMPATH programme.
Methods
Study design
The study was approved by the institutional research and
ethics committee of Moi Teaching and Referral Hospital and
Moi University School of Medicine. Since we were utilising only
anonymised data from the AMPATH and pharmacy databases,
the ethics committee allowed the study to be conducted without
individual patient consent. In addition to prescription data
(which were prospectively recorded by the AMPATH pro-
gramme), we also collected patient demographic data at
enrolment. In order to confirm that antiretrovirals were
dispensed and to record as completely as possible all co-
medications prescribed, we validated all clinical records against
AMPATH pharmacy records. Inclusion criteria for this study
were: HIV seropositive attending for care at Moi Teaching and
Referral Hospital, age .16 years, receiving antiretroviral
therapy. For this study, we screened the first 1040 consecutive
patients attending from 4th January 2006, with follow up over a
23 month period until 19th November 2007. Details of age,
gender, baseline weight, WHO stage, baseline CD4 count and
weight (if measured within 6 months of commencing antiretro-
viral therapy) and CD4 count and weight measurements nearest
to end of study period, together with all antiretrovirals and
concomitant medications were recorded. Under Kenyan
National AIDS and STI Control Programme (NASCOP)
guidelines, first-line antiretrovirals were defined as stavudine
(d4T) or zidovudine (ZDV) plus lamivudine (3TC) plus
nevirapine (NVP) or efavirenz (EFV), and substitution with
tenofovir (TDF), abacavir (ABC) or didanosine (ddI) was
allowed for toxicity. Second line included any of these agents
in combination with the protease inhibitors indinavir (IDV),
lopinavir/ritonavir (LPVr), or nelfinavir (NFV). The guidelines
for entry into the antiretroviral programme were: i) WHO Stage
1 or 2 HIV disease if CD4 count is ,200 cells/mm3, or ii)
WHO Stage 3 disease if CD4 is ,350 cells/mm3, or iii) WHO
Stage 4 disease, irrespective of the CD4 cell count [13]. All the
coprescribed drug pairs were screened for potential for CSDIs
using the Liverpool HIV Pharmacology Group website (www.
hiv-druginteractions.org) [14], accessed between January to
August 2008. This website comprises a comprehensive database
of ,5000 drug-interaction pairs, and uses a ‘traffic lights’ system
to flag up potential interactions. In order to avoid ‘overcalling’
the clinical significance of drug interactions, all interactions
which flagged up as red or amber were further scrutinised, and
the quality of evidence underpinning these recommendations
assessed using criteria derived from the GRADE system (http://
www.hiv-druginteractions.org/documents/QualityOfEvidence.
pdf) [15].
Classification of potential CSDIs
We searched the existing literature but could find no universally
accepted system for classifying severity of interactions. Some
publications have utilized a classification system by Tatro [16],
which grades severity according to illness or laboratory abnor-
malities caused by that interaction, and the potential consequences
of that toxicity (e.g. hospitalisation). We took the view that such a
classification was not appropriate to our study setting, since: i)
potentially serious adverse effects may be sub-clinical, delayed or
indirect with HIV therapy (such as low plasma concentrations
leading to rebound, resistance and loss of future therapeutic
options in a setting where access to second or third line regimens is
limited), ii) the threshold for admitting patients into hospital is
considerably different in Africa compared with developed
countries, and iii) clinical and laboratory monitoring is limited in
resource poor settings. We therefore utilised a modified version of
the Tatro severity classification as follows:
Major. Either potentially life-threatening, or capable of
causing permanent damage; or associated with significant
clinical toxicity (i.e. hospitalisation, extended hospital admission,
additional treatment); or ‘contraindicated’, ‘avoid’ or ‘not
recommended’ in the manufacturer’s SPC (Summary of Product
Characteristics; accessed from the Electronic Medicines
Compendium, emc.medicines.org.uk between January to August
2008); or requiring dose modification of at least one of the drugs
required in all/majority of the patients.
Moderate. Not a major interaction, but either capable of
causing deterioration in clinical status, or where the
manufacturer’s SPC advises ‘caution’, or ‘close monitoring’ for
toxicity or therapeutic failure.
‘‘Major’’ or ‘‘moderate’’ interactions were classified as ‘‘clini-
cally significant’’. We classified the remainder of patients as either
having no identified interactions or else minor interactions which
were defined as ‘‘not a major or moderate interaction, but having
usually mild consequences which may be bothersome but should
not significantly affect the therapeutic outcome without requiring
additional treatment.’’ Interactions relating solely to overlapping
toxicities, or between co-administered antiretrovirals (e.g. PI
boosting), or involving topical applications were excluded. In
addition, we excluded from our analysis potential interactions for
which controlled data suggested limited clinical significance (e.g.
lamivudine plus cotrimoxazole).
Statistical analysis
CD4 data were positively skewed so were log-transformed to
improve approximation to Normality. In order to characterise the
relationship between CD4 count and risk of drug interactions, the
prevalence of CSDIs (95% CI) was compared across CD4 deciles.
Patients were grouped according to whether they had a CSDI
versus no significant interaction. Differences in age and baseline
weight were assessed by Mann-Whitney U test, and in gender,
WHO Stage and drug regimen (first or second line) were assessed
by Fisher’s exact test. The prevalence of CSDIs across individual
NRTIs, NNRTIs and PIs were compared by Fisher’s exact test.
CD4 data were missing for 31 (3%) patients, weight for 11 (1%),
age for 106 (11%) patients and WHO Stage for 10 (1%) patients.
We therefore undertook multiple missing values imputation over
100 iterations prior to performing univariable and multivariable
analyses. Multivariable logistic regression was performed (with the
following covariates forced into the model: age, gender, baseline
weight, drug regimen, WHO Stage and log CD4 count) using the
PASW (SPPS version 17; SPSS Inc, Chicago, USA) statistical
package.
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Results
Of 1040 patients screened, 40 patients were excluded as they
were aged ,13 years, and a further 4 patients who discontinued
antiretrovirals during an acute opportunistic infection were also
excluded. A total of 996 patients were included in the final
analysis, comprising 346 (35%) male and 650 (65%) females aged
between 21–68 years (mean 39 years), mean body weight at
baseline of 58.1 kg (range 20–99 kg), and follow up for 1–22
months (median 15 months; total of 15,060 person-months).
Baseline CD4 counts were available for 965 patients with a
geometric mean count of 108 (range 0–1137) cells/mm3. During
follow up, the average change in CD4 count (95% CI) recorded
for 742 patients was +125 (112–138) cells and weight recorded for
720 patients was +3.1 (2.6–3.7) kg.
A total of 880 patients (88.4%) were on first-line antiretroviral
therapy, and 116 (11.6%) patients were on second line treatment.
The use of 1st line regimens were as follows: d4T/3TC/NVP in
504 patients (50.6%), d4T/3TC/EFV in 194 patients (19.5%),
3TC/ZDV/EFV in 44 patients (4.4%), ZDV/3TC/NVP in 128
patients (12.9%), ABC/3TC/NVP in 3 patients (0.3%), TDF/
3TC/EFV in 3 patients (0.3%) and TDF/3TC/NVP in 4 patients
(0.4%). Use of 2nd line treatments were as follows: 3TC/ZDV/
NFV in 34 patients (3.4%), ABC/ddI/LPVr in 28 patients (2.8%),
ABC/ZDV/LPVr in 16 patients (1.6%), d4T/3TC/LPVr in 2
patients (0.2%), NFV/3TC/d4T in 9 patients (0.9%), ZDV/3TC/
LPVr in 12 patients (1.2%), ZDV/ddI/LPVr in 14 patients (1.4%)
and ABC/3TC/LPVr in 1 patient (0.1%). Use of individual drugs
was as follows: d4T 709 (71.2%), 3TC 938 (94.2%), ZDV 248
(24.9%), NVP 639 (64.2%), EFV 241 (24.2%), TDF 7 (0.7%),
LPVr 70 (7.0%), NFV 43(4.3%), ddI 42 (4.2%) and ABC 48
(4.8%). All antiretrovirals were prescribed at standard doses,
regardless of whether a CSDI was present or not.
Risk for clinically significant interactions was identified in 334
patients (33.5%) with major interactions in 147 patients (14.8%),
predominantly involving rifampicin (124 patients; 12.4%) and
azoles (27 patients; 2.7%) (Table 1). Potential for moderate
interactions were identified in 230 patients (23.1%), involving
azoles in 129 patients (13%), steroids in 106 patients (10.6%) and
antimalarials in 29 patients (2.9%). No, or minor, drug interactions
were recorded in 662 patients (66.5%). Of the patients with
major/moderate interactions, 251 patients had one major/
moderate interaction recorded while 83 patients had more than
one, with 70 patients having two interactions, 11 patients three
interactions and two patients having four interactions.
Of the 432 CSDIs in 334 patients, 137 interactions occurring in
120 patients (35.9%) could potentially have resulted in decreased
antiretroviral exposure. Examples of these were: lopinavir/
ritonavir and rifampicin, nevirapine and rifampicin, nelfinavir
and omeprazole, nelfinavir and lansoprazole, and zidovudine and
rifampicin. In contrast to other studies [9,11], patients receiving
PIs were not more likely to have a CSDI. Excluding patients on
nelfinavir showed a comparable prevalence of CSDIs between
patients receiving lopinavir/ritonavir (31.5%), nevirapine (34.3%)
and efavirenz (36.5%). However, this probably masks considerable
differences in underlying patient characteristics - for example, co-
administration of rifampicin was more frequent with efavirenz
(76/241; 32%), compared to nevirapine (45/639; 7%) or
lopinavir/ritonavir (3/70; 2.6%. p,0.0001). Thus choice of
regimen was driven to a large degree by the need to manage
simultaneous tuberculosis (TB) and HIV treatment. Efavirenz with
rifampicin was in fact the most frequently encountered major
interaction (Table 1), and since this was prescribed in line with best
practice in HIV/TB co-infected patients, it could be argued that
this was an interaction which was being optimally managed.
Exclusion of the 40 patients in whom efavirenz plus rifampicin was
the sole CSDI yielded 294 patients (29.5%) with CSDIs.
Univariate analyses (Table 2) suggested that patients at risk of
CSDIs were significantly more likely to have a lower mean
baseline weight (56.0 vs 59.1 kg; p,0.001), lower CD4 count
(geometric mean 86 vs 120 cells/mm3; p,0.001) and more
advanced disease at WHO Stage 3 (48.8% vs 34.1%; p,0.001) or
Stage 4 (10.9% vs 7.0%; p,0.001). A weaker association was
observed between risk of CDSI and use of second line therapy
(p = 0.014). This may have been confounded by avoidance of PIs
in patients with tuberculosis, and the association was lost in
multivariate analyses. No significant association was observed
between risk for CDSIs and change in CD4 count or body weight,
and these covariates were not included in further analyses.
Amongst NRTIs, no single drug was significantly associated
with increased risk for CSDIs (Table 3). As numbers of patients
receiving tenofovir were low, Fisher’s test for significance was
carried out with and without these patients. There was also no
significant difference in risk for CSDIs between nevirapine and
efavirenz. Patients receiving nelfinavir were significantly less likely
to be at risk for a CSDI than those on lopinavir/ritonavir but
numbers were small, and the relevance of this finding is limited,
given that nelfinavir is no longer prescribed in most countries.
Multivariable logistic regression (Table 2) revealed that the risk
for CSDIs was significantly associated with female gender (68.0%
vs 63.9%; OR 1.506 [95% CI 1.097–2.065]; p = 0.010), low
baseline weight (OR 0.984 [0.970–0.998]; p = 0.023), low baseline
CD4 count (OR 0.839 [0.739–0.954]; p= 0.006) and disease stage
at WHO Stage 3 (OR 1.886 [1.327–2.683]; p,0.001) or Stage 4
(OR 2.085 [1.213–3.586]; p = 0.007). Analysis of the relationship
Table 1. Prevalence and Nature of Clinically Significant Drug
Interactions in Kenya.
Co-prescribed drug pairs
No. of interactions
(% of 432 CSDIs*)
Major interactions
LPVr + artemether/lumefantrine 1 (0.2)
LPVr + fluoxetine 2 (0.5)
LPVr + rifampicin 3 (0.7)
Efavirenz + rifampicin 76 (17.6)
Nelfinavir + lansoprazole 40.9)
Nelfinavir + omeprazole 4 (0.9)
Nevirapine + ketoconazole 27 (6.3)
Nevirapine + rifampicin 45 (10.4)
Moderate interactions
LPVr + ketoconazole 2 (0.5)
Efavirenz + ketoconazole 10 (2.3)
Efavirenz + artemether/lumefantrine 5 (1.2)
Nevirapine + artemether/lumefantrine 24 (5.6)
Nevirapine + fluconazole 97 (22.5)
Nevirapine + prednisone 106 (24.5)
Zidovudine + dapsone 1 (0.2)
Zidovudine + fluconazole 20 (4.6)
Zidovudine + rifampicin 5 (1.2)
*occurring in 334 individuals.
doi:10.1371/journal.pone.0016800.t001
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between CSDIs and CD4 decile (Figure 1) showed that the
prevalence of CSDIs increased with decreasing CD4 counts.
Discussion
Drug-drug interactions are one of the commonest causes of
medication error in developed countries, and antiretrovirals
among the most therapeutically risky drugs for clinically significant
drug interactions. Studies in the Netherlands and New York
involving 115 and 550 patients suggest a prevalence of 20–25%
CSDIs [7,8]. A second study in New York involving 153 patients
reported a prevalence of 41.2% [9]. Two recent studies conducted
in Liverpool (159 patients) and Switzerland (1497 patients)
reported a prevalence of CSDIs (including drug-drug interactions
between antiretroviral agents) of 26.3% and 40% respectively
[10,11]. Although definitions differed, four out of five of these
studies utilised the Liverpool Drug Interactions website to screen
for interactions. There have been no such studies in resource-
limited settings where risk is arguably increased as a result of less
laboratory monitoring, high rates of background illness (which
may result in adverse effects being missed), lack of affordable
alternative treatments, use of fixed dose combinations (that offer
less flexibility for managing interactions) and lack of pharmacov-
igilance data. In addition, there is a higher cost of treatment failure
in these settings, since options are limited compared with
developed countries. The purpose of our study was to investigate
the potential for CSDIs between antiretrovirals and co-adminis-
tered drugs in a large outpatient cohort in Kenya.
Table 2. Factors Associated with Risk for Developing a Clinically Significant Drug Interaction.
Variable Clinically significant drug interaction Odds ratio (95% CI) [p value]*
no yes unadjusted adjusted
Sample size 662 334
Sex: male n (%) 239 (36.1) 107 (32.0) --- ---
female n (%) 423 (63.9) 227 (68.0) 1.199 (0.902–1.592 [0.203] 1.506 (1.097–2.065) [0.010]
Age (y) mean (sd) 38.9 (9.2) 39.5 (8.6) 1.009 (0.993–1.025) [0.289] 1.010 (0.992–1.028) [0.243]
Weight (kg) mean (sd) 59.1 (10.7) 56.0 (10.5) 0.971 (0.958–0.985) [,0.001] 0.984 (0.970–0.998) [0.023]
CD4 (log units) mean (sd) 4.79 (1.10) 4.46 (1.21) 0.777 (0.690–0.874) [,0.001] 0.839 (0.739–0.954) [0.006]
WHO Stage: 1 n (%) 277 (42.2) 86 (26.1) --- ---
2 n (%) 109 (16.6) 47 (14.2) 1.386 (0.903–2.125) [0.127] 1.203 (0.776–1.865) [0.400]
3 n (%) 224 (34.1) 161 (48.8) 2.301 (1.667–3.174) [,0.001] 1.886 (1.327–2.683) [,0.001]
4 n (%) 46 (7.0) 36 (10.9) 2.507 (1.508–4.166) [,0.001] 2.085 (1.213–3.586) [0.007]
Regimen: 1st line n (%) 573 (86.6) 307 (91.9) --- ---
2nd line n (%) 89 (13.4) 27 (8.1) 0.566 (0.360–0.890) [0.014] 0.742 (0.457–1.203) [0.218]
Summary statistics are based on original data (ignoring the missing observations). However, both the unadjusted (univariate) and adjusted (bivariate) odds ratios (and
their 95% confidence intervals) were computed after a multiple imputation analysis (of 100 iterations) to replace the missing observations for age, CD4 count, weight
and WHO Stage. The odds ratios were computed using logistic regression models (with all variables forced into the model in the adjusted/multivariate analysis).
*: missing observations replaced using multiple imputation (100 iterations).
doi:10.1371/journal.pone.0016800.t002
Table 3. Risk of Clinically Significant Drug Interaction by Individual Drug.
Antiretroviral drug Total no. of patients
Clinically significant drug interaction
N (%; 95% CI) p value{
NRTIs
Abacavir (ABC) 48 14 (29.2%; 17.0–44.1)
Didanosine (ddI) 42 18 (42.9%; 27.7–59.0) all NRTIs
Lamivudine (3TC) 938 313 (33.4%; 30.4–36.5) 0.547
Stavudine (d4T) 709 239 (33.7%; 30.2–37.3)
Zidovudine (ZDV) 248 80 (32.3%; 26.5–38.5) excluding TDF
Tenofovir (TDF) 7 4 (57.1%; 18.4–90.1) 0.694
NNRTIs
Efavirenz (EFV) 241 88 (36.5%; 30.4 – 42.9) 0.579
Nevirapine (NVP) 639 219 (34.3%; 30.6–38.1)
PIs
Lopinavir (LPVr) 73 23 (31.5%; 21.1–43.4) 0.006
Nelfinavir (NFV) 43 4 (9.3%; 2.6–22.1)
{: Fisher exact test.
doi:10.1371/journal.pone.0016800.t003
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In Africa, the concurrent epidemics of HIV, TB and malaria to
a large degree make CSDIs unavoidable. We observed that risk for
CSDIs was prevalent in the patients studied, affecting one in three
patients. Of particular concern, these interactions could have
resulted in lowering of plasma concentrations of antiretrovirals
(thus increasing the risk of HIV treatment failure) in over a third of
patients with CSDIs. Although the repertoire of available drugs
may be more limited, risk of adverse outcome resulting from
CSDIs is arguably higher in resource-poor settings due to lack of
intensive laboratory monitoring, presence of overlapping syn-
dromes such as fever (which may confound the correct
identification of adverse events), late presentation of HIV, high
background of other illness and use of traditional medicines and
antimalarials in the community. Patients with advanced (WHO
Stage 3 or 4) disease were approximately twice as likely to be at
risk of a CSDI. Risk was increased with low CD4 count, but there
were also weaker correlations with low baseline weight, and female
gender. Furthermore, the use of fixed dose combinations of
antiretrovirals gives little scope for dose-modification as a strategy
for managing these interactions.
Most of the major interactions involved interactions between
antiretrovirals and rifampicin in patients who were being treated
for TB. Despite the growing number of clinical trials assessing
novel TB drugs, there is still no credible alternative to
rifamycin-based therapy, and this remained the predominant
cause of CSDIs in our study. Use of nevirapine with rifampicin
remains prevalent in sub-Saharan Africa. Pending results from
comparative trials (without nevirapine lead-in dosing), efavir-
enz-based regimens are preferred since they have been shown to
be effective, and less affected by rifampicin. Rifampicin was
reported to decrease nevirapine AUC concentrations by 58%
[17,18] and efavirenz AUC by 26% [19], but virological
outcomes in people receiving standard dose efavirenz and
rifampicin are comparable with patients commencing antiret-
rovirals without TB [20].
In patients with NNRTI resistance, treatment choices in
resource poor settings are difficult, balancing an increased risk of
HIV treatment failure against unaffordable drug costs. NRTI-only
regimens may be an option for the duration of rifampicin therapy
for those in whom prior resistance is unlikely. Double-dose LPVr
has been proposed but not formally evaluated for adult patients
(drug exposure in very young children was found to be inadequate
[21,22]). Added ritonavir boosting may also be an option in some
health settings. Newer drugs such as raltegravir and maraviroc are
not affordable options for most treatment programmes in sub-
Saharan Africa. Substituting rifampicin with rifabutin is effective
in predominantly HIV-negative or untested cohorts [23] but is also
currently unaffordable for many health care settings. The optimal
dosing of rifabutin with LPVr is currently a subject of debate [24].
The widespread use of azoles, (either as treatment for Candida
infections, or prophylaxis against cryptococcal disease) also
accounted for a significant number of interactions. Interactions
involving nevirapine and fluconazole were identified in 97 patients
(9.7%), while nevirapine and ketoconazole were recorded for 27
patients (2.7%). Nevirapine has been reported to decrease
ketoconazole concentrations by 72% upon coadministration [25]
and the combination is contraindicated in the manufacturer’s
SPC. We have recently reported that co-administration of
fluconazole and nevirapine resulted in a 33% increase in
nevirapine AUC0–8h compared to when nevirapine was adminis-
tered alone [26] and therefore there is potential for toxicity.
Artemether-combination therapies have replaced sulfadoxine/
pyrimethamine as first line antimalarials, and have the potential
for clinically relevant pharmacokinetic interactions and toxicity
with HIV PIs and NNRTIs. The AUC of lumefantrine increased
by 193% in a study when lopinavir/ritonavir was coadministered
with artemether/lumefantrine, since lumefantrine is extensively
metabolized by CYP3A4 and PIs inhibit CYP3A4 [27], and the
manufacturer’s SPC advises that the combination is contraindi-
cated. Of the other interactions, proton pump inhibitors were
Figure 1. Odds Ratios for Clinically Significant Drug Interaction by CD4 Count Decile.
doi:10.1371/journal.pone.0016800.g001
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important; mainly with nelfinavir, a PI no longer in widespread
use in developed countries but may become an increasing problem
if atazanavir is used in second line regimens.
There are several limitations to our study. It is important to note
that we studied the potential for CSDIs, and did not monitor for
adverse outcomes arising from these interactions. Specifically our
lack of ability to closely monitor viral load and liver biochemistry
rendered us unable to assess the impact of adverse interactions.
We did not observe any relationship between risk for CSDIs and
response to therapy (as measured by CD4 count and weight gain)
but these measures of efficacy are insensitive, do not correlate
tightly with HIV viral load, and were missing in over a quarter of
our patients. Current WHO guidance and national policy in
Kenya recommends the use of efavirenz (without weight-based
dose modifications) when using rifampicin for TB co-infection.
Thus, these drugs were prescribed in accordance with existing best
practice even though they would have appeared as major
interactions in our series (excluding these patients did not
significantly affect the prevalence of patients at risk of CSDIs).
We did not actively seek information on the use of antimalarials, or
herbal or traditional medicines in the community, and the use of
oral/injectable contraceptives was almost certainly incompletely
recorded. We also did not include drug interactions between the
non-HIV medications. Finally, we did not ascertain whether the
patients were receiving treatment elsewhere other than the HIV
clinic. Our findings may therefore represent an underestimation of
the true incidence of potentially significant drug interactions in this
cohort of patients.
We observed a prevalence of 11.6% patients on second line (PI-
based) regimens which is comparable to a frequency of switch to
PI-based second-line regimens of 11.4% at 36 months in 5484
children in the IeDEA cohort in South Africa [28], 1.7% at 2 years
in 1,045 adults in the Home-based AIDS Care cohort from
Eastern Uganda [29], and 19–22% of 3321 patients enrolled into
the DART study [30]. WHO guidelines have recently been revised
to reflect the potential future expansion of therapeutic options
(based around increased PI use) for those who fail first line therapy
[31]. Thus, the problem of CSDIs is not likely to diminish in the
near future.
Use of therapeutic drug monitoring is not feasible as a strategy
for managing CSDIs in resource-poor settings. Practical steps that
can be instituted to reduce the risk of adverse outcomes from
CSDIs include integrating national treatment programmes for
HIV and other diseases (with protocols that minimise drug
interactions), establishing regional networks for pharmacovigi-
lance, and improving the quality of prescribing through training
and education of health care workers. Knowledge of common
interactions involving antiretrovirals on a country-specific basis
will allow targeted training, monitoring and protocol development.
Finally, we believe that large antiretroviral programmes should
undertake an audit of clinically significant drug interactions as a
proxy for the quality of prescribing within that scheme.
In summary, one in three patients receiving antiretroviral
therapy in Kenya were at risk of CSDIs, (which had the potential
to lower HIV drug concentrations in 12% patients). Although TB
medications accounted for a significant proportion of CSDIs, we
identified other important interactions involving antiretrovirals
such as azoles, and antimalarials. Surveys in other large cohorts
are required to confirm whether these findings are generalisable to
other African HIV treatment settings. Strategies need to urgently
be developed to avoid important CSDIs, to identify early markers
of toxicity and to manage unavoidable interactions safely in order
to reduce risk of harm, and to maximize the effectiveness of mass
antiretroviral deployment in Africa.
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